Evommune Announces $125 Million Private Placement
Evommune, Inc. (EVMN)
Company Research
Source: Business Wire
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as placement agents for the private placeme
Show less
Read more
Impact Snapshot
Event Time:
EVMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVMN alerts
High impacting Evommune, Inc. news events
Weekly update
A roundup of the hottest topics
EVMN
News
- Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
- Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic DermatitisBusiness Wire
- Evommune (NYSE:EVMN) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e)" rating on the stock.MarketBeat
EVMN
Sec Filings
- 2/19/26 - Form 4
- 2/19/26 - Form SCHEDULE
- 2/18/26 - Form 4
- EVMN's page on the SEC website